DNA Integrity As Biomarker in Pancreatic Cyst Fluid

Overview

Journal Am J Cancer Res

Specialty Oncology

Date 2016 Sep 21

PMID 27648370

Citations 7

Authors

Wesley K Utomo

Vincent T Janmaat

Auke P Verhaar

Jerome Cros

Philippe Levy

Philippe Ruszniewski

Mirella S Vredenbregt-van den Berg

Guido Jenster

Marco J Bruno

Henri Braat

Gwenny M Fuhler

Maikel P Peppelenbosch

Affiliations

Soon will be listed here.

Abstract

Identification of pancreatic cysts with malignant potential is important to prevent pancreatic cancer development. Integrity of cell free DNA (cfDNA) has been described as tumor biomarker, but its potential for pancreatic cancer is unclear. While normal apoptotic cells release uniformly truncated DNA, malignant tissues release long fragments of cell free DNA (cfDNA). We measured 247 base pair (bp) and 115 bp DNA fragments of ALU repeats by qPCR in serum from healthy controls and pancreatic cancer patients, and in cyst fluid from pancreatic cyst patients. No differences in total cfDNA (ALU115) and cfDNA integrity (ALU247/115) were observed between sera from healthy controls (n=19) and pancreatic cancer patients (n=19). Although elevated as compared to serum, but no differences in cfDNA were found in cyst fluid from high risk (n=10) and low risk (n=20) cyst patients. We conclude that cfDNA integrity is not a useful marker to identify (pre)malignant pancreatic lesions.

Citing Articles

Evaluating circulating cell-free DNA and DNA integrity index as biomarkers in non-small cell lung cancer.

Ezzeldin N, El-Lebedy D, Hassan M, Shalaby A, Hussein S, Gharib A J Egypt Natl Canc Inst. 2024; 36(1):21.

PMID: 38880832 DOI: 10.1186/s43046-024-00219-1.

Cancer-cell-derived cell-free DNA can predict distant metastasis earlier in pancreatic cancer: a prospective cohort study.

Huang C, Huang W, Chen C, Chao Y, Chiang N, Shan Y Ther Adv Med Oncol. 2022; 14:17588359221106558.

PMID: 35747164 PMC: 9210094. DOI: 10.1177/17588359221106558.

ALU repeat as potential molecular marker in the detection and prognosis of different cancer types: A systematic review.

Shaban S, Al-Rahim A, Suleiman A Mol Clin Oncol. 2022; 16(4):86.

PMID: 35251637 PMC: 8892463. DOI: 10.3892/mco.2022.2519.

Liquid biopsy in cancer using the Z-scan technique: a new approach to discover biomarkers in cancer.

Fonseca F, da Veiga G, Alves B, Alves S Future Sci OA. 2021; 7(1):FSO638.

PMID: 33437502 PMC: 7787153. DOI: 10.2144/fsoa-2020-0054.

Prognostic value of the DNA integrity index in patients with malignant lung tumors.

Chudasama D, Aladag Z, Felicien M, Hall M, Beeson J, Asadi N Oncotarget. 2018; 9(30):21281-21288.

PMID: 29765538 PMC: 5940399. DOI: 10.18632/oncotarget.25086.

References

SORENSON G, Pribish D, Valone F, Memoli V, Bzik D, Yao S . Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomarkers Prev. 1994; 3(1):67-71. View

Roobol M, Kranse R, Bangma C, van Leenders A, Blijenberg B, van Schaik R . Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer. Eur Urol. 2013; 64(4):530-9. DOI: 10.1016/j.eururo.2013.05.030. View

Sikora K, Bedin C, Vicentini C, Malpeli G, DAngelo E, Sperandio N . Evaluation of cell-free DNA as a biomarker for pancreatic malignancies. Int J Biol Markers. 2014; 30(1):e136-41. DOI: 10.5301/jbm.5000088. View

Giacona M, Ruben G, Iczkowski K, Roos T, Porter D, SORENSON G . Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. Pancreas. 1998; 17(1):89-97. DOI: 10.1097/00006676-199807000-00012. View

Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer F, Hesch R . DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001; 61(4):1659-65. View

Roobol M, Schroder F . European Randomized Study of Screening for Prostate Cancer: achievements and presentation. BJU Int. 2004; 92 Suppl 2:117-22. DOI: 10.1111/j.1464-410x.2003.4698x.x. View

da Silva Filho B, Gurgel A, Neto M, de Azevedo D, Freitas A, Silva Neto J . Circulating cell-free DNA in serum as a biomarker of colorectal cancer. J Clin Pathol. 2013; 66(9):775-8. DOI: 10.1136/jclinpath-2013-201521. View

Agostini M, Enzo M, Bedin C, Belardinelli V, Goldin E, Del Bianco P . Circulating cell-free DNA: a promising marker of regional lymphonode metastasis in breast cancer patients. Cancer Biomark. 2012; 11(2-3):89-98. DOI: 10.3233/CBM-2012-0263. View

Utomo W, Braat H, Bruno M, van Eijck C, Groot Koerkamp B, Krak N . Cytopathological Analysis of Cyst Fluid Enhances Diagnostic Accuracy of Mucinous Pancreatic Cystic Neoplasms. Medicine (Baltimore). 2015; 94(24):e988. PMC: 4616542. DOI: 10.1097/MD.0000000000000988. View

10.

Shapiro B, Chakrabarty M, COHN E, Leon S . Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer. 1983; 51(11):2116-20. DOI: 10.1002/1097-0142(19830601)51:11<2116::aid-cncr2820511127>3.0.co;2-s. View

11.

Hormozdiari F, Alkan C, Ventura M, Hajirasouliha I, Malig M, Hach F . Alu repeat discovery and characterization within human genomes. Genome Res. 2010; 21(6):840-9. PMC: 3106317. DOI: 10.1101/gr.115956.110. View

12.

Umetani N, Kim J, Hiramatsu S, Reber H, Hines O, Bilchik A . Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. Clin Chem. 2006; 52(6):1062-9. DOI: 10.1373/clinchem.2006.068577. View

13.

Spindler K, Pallisgaard N, Andersen R, Brandslund I, Jakobsen A . Circulating free DNA as biomarker and source for mutation detection in metastatic colorectal cancer. PLoS One. 2015; 10(4):e0108247. PMC: 4395277. DOI: 10.1371/journal.pone.0108247. View

14.

Iqbal S, Vishnubhatla S, Raina V, Sharma S, Gogia A, Deo S . Circulating cell-free DNA and its integrity as a prognostic marker for breast cancer. Springerplus. 2015; 4:265. PMC: 4469592. DOI: 10.1186/s40064-015-1071-y. View